import React from 'react';

// ‚îÄ‚îÄ‚îÄ MPN Deep Dive Educational Content ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
const MPNDeepDive: React.FC = () => (
    <div className="space-y-8">
        {/* Section 1: What Are MPNs? */}
        <section className="bg-white rounded-2xl shadow-sm border border-gray-200 p-8">
            <h2 className="text-2xl font-bold text-gray-900 mb-4 flex items-center gap-2">
                <span className="text-rose-600">üî¨</span> Understanding MPNs ‚Äî Overproduction, Not Failure
            </h2>
            <p className="text-gray-700 text-lg leading-relaxed mb-4">
                Myeloproliferative Neoplasms are the <strong>opposite of MDS</strong>. While MDS features bone marrow
                that fails to produce mature cells, MPNs are characterized by <strong>overproduction of mature,
                    functional blood cells</strong>. The bone marrow is too active, producing excess quantities of one
                or more blood cell lineages ‚Äî red blood cells, platelets, or white blood cells ‚Äî leading to
                thickened blood, clotting risks, and eventual marrow scarring.
            </p>

            <div className="grid grid-cols-1 md:grid-cols-3 gap-4 my-6">
                <div className="bg-red-50 p-5 rounded-xl border border-red-100 text-center">
                    <div className="text-3xl mb-2">ü©∏</div>
                    <h4 className="font-bold text-red-800 mb-1">Polycythemia Vera (PV)</h4>
                    <p className="text-sm text-red-700">
                        <strong>Too many red blood cells</strong><br />
                        Thick blood ‚Üí clotting risk<br />
                        JAK2 V617F in &gt;95%
                    </p>
                </div>
                <div className="bg-amber-50 p-5 rounded-xl border border-amber-100 text-center">
                    <div className="text-3xl mb-2">ü©π</div>
                    <h4 className="font-bold text-amber-800 mb-1">Essential Thrombocythemia (ET)</h4>
                    <p className="text-sm text-amber-700">
                        <strong>Too many platelets</strong><br />
                        Clotting + paradoxical bleeding<br />
                        JAK2, CALR, or MPL mutations
                    </p>
                </div>
                <div className="bg-purple-50 p-5 rounded-xl border border-purple-100 text-center">
                    <div className="text-3xl mb-2">ü¶¥</div>
                    <h4 className="font-bold text-purple-800 mb-1">Myelofibrosis (MF)</h4>
                    <p className="text-sm text-purple-700">
                        <strong>Bone marrow scarring</strong><br />
                        Fibrosis replaces marrow ‚Üí cytopenias<br />
                        Most aggressive classic MPN
                    </p>
                </div>
            </div>

            <div className="bg-gray-50 p-5 rounded-xl border border-gray-200">
                <h4 className="font-bold text-gray-900 mb-2">üìù Note: CML Is Also an MPN</h4>
                <p className="text-sm text-gray-700">
                    Chronic Myeloid Leukemia was historically classified as an MPN but is now treated as a distinct
                    entity because of its <strong>unique biology (BCR-ABL1)</strong> and specific treatment (TKIs).
                    The "classic" BCR-ABL1-negative MPNs discussed here are PV, ET, and MF. These share overlapping
                    features and can <strong>evolve from one into another</strong> over time.
                </p>
            </div>
        </section>

        {/* Section 2: The Driver Mutations */}
        <section className="bg-white rounded-2xl shadow-sm border border-gray-200 p-8">
            <h2 className="text-2xl font-bold text-gray-900 mb-4 flex items-center gap-2">
                <span className="text-emerald-600">üß¨</span> The Three Driver Mutations
            </h2>
            <p className="text-gray-700 text-lg leading-relaxed mb-4">
                ~90% of MPNs are driven by a mutation in one of <strong>three genes</strong> ‚Äî all converging on the
                same pathway: constitutive activation of <strong>JAK-STAT signaling</strong>, which drives
                uncontrolled blood cell production. These mutations are <strong>mutually exclusive</strong> ‚Äî a
                patient carries one or none.
            </p>

            <div className="space-y-4 my-6">
                <div className="bg-emerald-50 p-5 rounded-xl border border-emerald-100">
                    <div className="flex items-center gap-2 mb-2">
                        <span className="px-2 py-0.5 bg-emerald-600 text-white rounded-md text-xs font-bold">MOST COMMON</span>
                        <h4 className="font-bold text-emerald-800">JAK2 V617F (~60% of MPNs)</h4>
                    </div>
                    <p className="text-sm text-emerald-700 mb-2">
                        A single point mutation in the <strong>Janus Kinase 2</strong> gene that removes the
                        auto-inhibitory function of the pseudokinase domain. The result: JAK2 is <strong>always
                            turned on</strong>, continuously sending growth signals regardless of cytokine input.
                    </p>
                    <ul className="text-sm text-emerald-700 space-y-1 pl-4">
                        <li>‚Ä¢ Present in <strong>&gt;95% of PV</strong>, ~55% of ET, ~65% of MF</li>
                        <li>‚Ä¢ Discovered in 2005 ‚Äî transformed MPN diagnosis</li>
                        <li>‚Ä¢ <strong>Allele burden matters</strong>: homozygous JAK2 (two copies) is associated with PV phenotype and higher risk</li>
                        <li>‚Ä¢ JAK2 exon 12 mutations: rare variants found in ~3% of PV patients without V617F</li>
                    </ul>
                </div>
                <div className="bg-blue-50 p-5 rounded-xl border border-blue-100">
                    <div className="flex items-center gap-2 mb-2">
                        <span className="px-2 py-0.5 bg-blue-600 text-white rounded-md text-xs font-bold">2ND MOST COMMON</span>
                        <h4 className="font-bold text-blue-800">CALR Mutations (~25% of MPNs)</h4>
                    </div>
                    <p className="text-sm text-blue-700 mb-2">
                        Mutations in <strong>calreticulin</strong> ‚Äî an endoplasmic reticulum chaperone protein.
                        Mutant CALR binds to the <strong>MPL (thrombopoietin receptor)</strong> and activates
                        JAK-STAT signaling constitutively:
                    </p>
                    <ul className="text-sm text-blue-700 space-y-1 pl-4">
                        <li>‚Ä¢ Found in ~25-30% of ET and ~25-30% of MF; <strong>not found in PV</strong></li>
                        <li>‚Ä¢ <strong>Type 1 (52-bp deletion)</strong>: more common in MF, intermediate prognosis</li>
                        <li>‚Ä¢ <strong>Type 2 (5-bp insertion)</strong>: more common in ET, generally favorable prognosis</li>
                        <li>‚Ä¢ CALR-mutated ET has the <strong>lowest thrombosis risk</strong> of all MPN genotypes</li>
                    </ul>
                </div>
                <div className="bg-violet-50 p-5 rounded-xl border border-violet-100">
                    <div className="flex items-center gap-2 mb-2">
                        <span className="px-2 py-0.5 bg-violet-600 text-white rounded-md text-xs font-bold">LEAST COMMON</span>
                        <h4 className="font-bold text-violet-800">MPL Mutations (~5% of MPNs)</h4>
                    </div>
                    <p className="text-sm text-violet-700">
                        Mutations in the <strong>thrombopoietin receptor (MPL)</strong> itself ‚Äî most commonly
                        W515L/K ‚Äî that cause the receptor to signal without binding thrombopoietin. Found in
                        ~3-5% of ET and ~5-8% of MF. Never found in PV. Associated with older age, lower
                        hemoglobin, and higher platelet counts.
                    </p>
                </div>
                <div className="bg-gray-50 p-5 rounded-xl border border-gray-200">
                    <div className="flex items-center gap-2 mb-2">
                        <span className="px-2 py-0.5 bg-gray-600 text-white rounded-md text-xs font-bold">~10%</span>
                        <h4 className="font-bold text-gray-800">"Triple Negative" MPNs</h4>
                    </div>
                    <p className="text-sm text-gray-700">
                        About 10% of ET and 10% of MF patients lack all three driver mutations. These
                        <strong>"triple negative"</strong> cases often have non-canonical JAK-STAT pathway mutations
                        and carry the <strong>worst prognosis</strong> in myelofibrosis ‚Äî associated with higher
                        leukemic transformation risk and shorter survival.
                    </p>
                </div>
            </div>
        </section>

        {/* Section 3: Polycythemia Vera Deep Dive */}
        <section className="bg-white rounded-2xl shadow-sm border border-gray-200 p-8">
            <h2 className="text-2xl font-bold text-gray-900 mb-4 flex items-center gap-2">
                <span className="text-red-600">ü©∏</span> Polycythemia Vera (PV) ‚Äî Too Many Red Cells
            </h2>
            <p className="text-gray-700 text-lg leading-relaxed mb-4">
                PV is characterized by <strong>uncontrolled red blood cell production</strong>, leading to dangerously
                thick blood. It is the most common MPN, with a median age at diagnosis of ~60 years. The overproduction
                of red cells increases blood viscosity, causing the hallmark risk of <strong>thrombosis</strong> ‚Äî the
                leading cause of morbidity and mortality.
            </p>

            <div className="grid grid-cols-1 md:grid-cols-2 gap-4 my-4">
                <div className="bg-red-50 p-5 rounded-xl border border-red-100">
                    <h4 className="font-bold text-red-800 mb-2">‚ö†Ô∏è Symptoms & Presentation</h4>
                    <ul className="text-sm text-red-700 space-y-2">
                        <li>‚Ä¢ <strong>Headache, dizziness, visual disturbances</strong> ‚Äî from hyperviscosity</li>
                        <li>‚Ä¢ <strong>Aquagenic pruritus</strong> ‚Äî intense itching after bathing, often the most
                            distressing symptom; caused by mast cell activation</li>
                        <li>‚Ä¢ <strong>Erythromelalgia</strong> ‚Äî burning pain and redness in hands/feet</li>
                        <li>‚Ä¢ <strong>Plethoric (ruddy) complexion</strong></li>
                        <li>‚Ä¢ <strong>Splenomegaly</strong> (~70%)</li>
                        <li>‚Ä¢ <strong>Thrombosis</strong> ‚Äî stroke, MI, DVT/PE, hepatic vein (Budd-Chiari), portal vein</li>
                    </ul>
                </div>
                <div className="bg-orange-50 p-5 rounded-xl border border-orange-100">
                    <h4 className="font-bold text-orange-800 mb-2">üíä PV Treatment</h4>
                    <ul className="text-sm text-orange-700 space-y-2">
                        <li>‚Ä¢ <strong>Phlebotomy</strong> ‚Äî first-line for ALL PV patients; target hematocrit &lt;45%
                            (CYTO-PV trial showed this reduces cardiovascular events by 4√ó)</li>
                        <li>‚Ä¢ <strong>Low-dose aspirin</strong> ‚Äî all patients unless contraindicated; reduces thrombosis
                            risk (ECLAP trial)</li>
                        <li>‚Ä¢ <strong>Hydroxyurea</strong> ‚Äî cytoreductive therapy for high-risk PV (age ‚â•60 or prior
                            thrombosis)</li>
                        <li>‚Ä¢ <strong>Interferon alfa / Ropeginterferon</strong> ‚Äî preferred in younger patients; can
                            reduce JAK2 allele burden and achieve molecular responses</li>
                        <li>‚Ä¢ <strong>Ruxolitinib (Jakafi¬Æ)</strong> ‚Äî for hydroxyurea-resistant/intolerant PV; controls
                            hematocrit, reduces spleen, and alleviates symptoms</li>
                    </ul>
                </div>
            </div>

            <div className="bg-amber-50 p-5 rounded-xl border border-amber-100">
                <h4 className="font-bold text-amber-900 mb-2">üîÑ Disease Evolution</h4>
                <p className="text-sm text-amber-800">
                    PV can evolve into <strong>post-PV myelofibrosis</strong> (~10-15% at 15 years), characterized
                    by progressive bone marrow fibrosis, splenomegaly, and worsening cytopenias. Transformation to
                    <strong> AML</strong> occurs in ~3-5% of patients at 15 years (higher with certain treatments
                    like prolonged alkylating agent exposure).
                </p>
            </div>
        </section>

        {/* Section 4: Essential Thrombocythemia Deep Dive */}
        <section className="bg-white rounded-2xl shadow-sm border border-gray-200 p-8">
            <h2 className="text-2xl font-bold text-gray-900 mb-4 flex items-center gap-2">
                <span className="text-amber-600">ü©π</span> Essential Thrombocythemia (ET) ‚Äî Too Many Platelets
            </h2>
            <p className="text-gray-700 text-lg leading-relaxed mb-4">
                ET is characterized by <strong>sustained overproduction of platelets</strong>, often with counts
                exceeding 450,000/ŒºL (normal: 150,000-400,000). Despite having the most indolent course of the
                classic MPNs, ET carries significant thrombotic risk and the paradox of <strong>both clotting
                    and bleeding complications</strong>.
            </p>

            <div className="grid grid-cols-1 md:grid-cols-2 gap-4 my-4">
                <div className="bg-amber-50 p-5 rounded-xl border border-amber-100">
                    <h4 className="font-bold text-amber-800 mb-2">üß™ The Thrombosis-Bleeding Paradox</h4>
                    <p className="text-sm text-amber-700 mb-2">
                        While moderate platelet elevations increase clotting risk, <strong>extremely high counts
                            (&gt;1,000,000-1,500,000/ŒºL)</strong> can paradoxically cause <strong>bleeding</strong>
                        through acquired von Willebrand syndrome ‚Äî large vWF multimers are consumed by the excess
                        platelets. This is why aspirin must be used cautiously at very high platelet counts.
                    </p>
                </div>
                <div className="bg-teal-50 p-5 rounded-xl border border-teal-100">
                    <h4 className="font-bold text-teal-800 mb-2">üíä ET Treatment Strategy</h4>
                    <ul className="text-sm text-teal-700 space-y-2">
                        <li>‚Ä¢ <strong>Low risk (age &lt;60, no prior thrombosis)</strong>: observation ¬± aspirin</li>
                        <li>‚Ä¢ <strong>High risk</strong>: cytoreduction with hydroxyurea (first-line), anagrelide
                            (second-line ‚Äî selectively reduces platelet production), or interferon alfa</li>
                        <li>‚Ä¢ <strong>CALR-mutated, young patients</strong> may be safely observed even without aspirin
                            ‚Äî they have the lowest thrombosis risk</li>
                    </ul>
                </div>
            </div>

            <div className="bg-sky-50 p-5 rounded-xl border border-sky-100">
                <h4 className="font-bold text-sky-900 mb-2">üìä Risk Stratification (IPSET-thrombosis)</h4>
                <p className="text-sm text-sky-800">
                    The revised IPSET-thrombosis model stratifies ET patients into 4 risk categories based on
                    <strong> age, thrombosis history, JAK2 status, and cardiovascular risk factors</strong>:
                    Very Low (CALR+, age &lt;60, no thrombosis), Low (JAK2‚àí, age &lt;60), Intermediate
                    (JAK2+, age &lt;60), and High (age ‚â•60 or prior thrombosis). Only high-risk patients
                    clearly benefit from cytoreduction.
                </p>
            </div>
        </section>

        {/* Section 5: Myelofibrosis Deep Dive */}
        <section className="bg-white rounded-2xl shadow-sm border border-gray-200 p-8">
            <h2 className="text-2xl font-bold text-gray-900 mb-4 flex items-center gap-2">
                <span className="text-purple-600">ü¶¥</span> Myelofibrosis (MF) ‚Äî Bone Marrow Scarring
            </h2>
            <p className="text-gray-700 text-lg leading-relaxed mb-4">
                Myelofibrosis is the <strong>most aggressive</strong> classic MPN. It can arise de novo
                (<strong>primary MF</strong>) or evolve from prior PV or ET (<strong>post-PV MF</strong> or
                <strong> post-ET MF</strong>). The hallmark is progressive <strong>bone marrow fibrosis</strong> ‚Äî
                scar tissue replaces normal marrow, forcing blood production to shift to the spleen and liver
                (extramedullary hematopoiesis), causing massive organ enlargement.
            </p>

            <div className="grid grid-cols-1 md:grid-cols-2 gap-4 my-4">
                <div className="bg-purple-50 p-5 rounded-xl border border-purple-100">
                    <h4 className="font-bold text-purple-800 mb-2">‚ö†Ô∏è Clinical Features</h4>
                    <ul className="text-sm text-purple-700 space-y-2">
                        <li>‚Ä¢ <strong>Massive splenomegaly</strong> ‚Äî often extending below the umbilicus; causes
                            early satiety, abdominal pain, and portal hypertension</li>
                        <li>‚Ä¢ <strong>Constitutional symptoms</strong> ‚Äî debilitating fatigue, night sweats, bone pain,
                            weight loss, and fevers (cytokine-driven)</li>
                        <li>‚Ä¢ <strong>Anemia</strong> ‚Äî progressive, often transfusion-dependent</li>
                        <li>‚Ä¢ <strong>Leukoerythroblastic blood smear</strong> ‚Äî teardrop-shaped red cells
                            (dacrocytes) and circulating immature myeloid cells</li>
                        <li>‚Ä¢ <strong>"Dry tap"</strong> on bone marrow aspiration ‚Äî the fibrotic marrow cannot be aspirated</li>
                    </ul>
                </div>
                <div className="bg-indigo-50 p-5 rounded-xl border border-indigo-100">
                    <h4 className="font-bold text-indigo-800 mb-2">üìä Risk Stratification (DIPSS / MIPSS70+)</h4>
                    <p className="text-sm text-indigo-700 mb-2">
                        Multiple scoring systems guide treatment:
                    </p>
                    <ul className="text-sm text-indigo-700 space-y-1 pl-4">
                        <li>‚Ä¢ <strong>DIPSS</strong>: age, symptoms, hemoglobin, WBC, blood blasts</li>
                        <li>‚Ä¢ <strong>MIPSS70+ v2.0</strong>: adds cytogenetics + mutations (ASXL1, SRSF2, EZH2, IDH1/2, U2AF1)</li>
                        <li>‚Ä¢ <strong>High-molecular-risk (HMR) mutations</strong>: ‚â•1 of ASXL1, SRSF2, EZH2, IDH1/2 ‚Äî independently shortens survival</li>
                        <li>‚Ä¢ Risk determines transplant candidacy ‚Äî the only curative therapy</li>
                    </ul>
                </div>
            </div>

            <div className="bg-teal-50 p-5 rounded-xl border border-teal-100">
                <h4 className="font-bold text-teal-800 mb-3">üíä MF Treatment Landscape</h4>
                <div className="grid grid-cols-1 md:grid-cols-2 gap-3">
                    <div className="bg-white p-3 rounded-lg border border-teal-200">
                        <h5 className="font-semibold text-teal-900 text-sm mb-1">Ruxolitinib (Jakafi¬Æ)</h5>
                        <p className="text-xs text-teal-700">
                            First-line JAK1/2 inhibitor. Dramatically reduces <strong>splenomegaly</strong> (~35% volume
                            reduction in COMFORT trials) and <strong>constitutional symptoms</strong>. Modestly improves
                            survival. Does not eliminate the MF clone or reverse fibrosis.
                        </p>
                    </div>
                    <div className="bg-white p-3 rounded-lg border border-teal-200">
                        <h5 className="font-semibold text-teal-900 text-sm mb-1">Fedratinib (Inrebic¬Æ)</h5>
                        <p className="text-xs text-teal-700">
                            JAK2-selective inhibitor. Effective as <strong>second-line after ruxolitinib failure</strong>.
                            Requires monitoring for Wernicke's encephalopathy risk (thiamine levels).
                        </p>
                    </div>
                    <div className="bg-white p-3 rounded-lg border border-teal-200">
                        <h5 className="font-semibold text-teal-900 text-sm mb-1">Pacritinib (Vonjo¬Æ)</h5>
                        <p className="text-xs text-teal-700">
                            JAK2/IRAK1 inhibitor uniquely suited for patients with <strong>severe thrombocytopenia
                                (platelets &lt;50,000)</strong> ‚Äî where ruxolitinib cannot be safely dosed. The only JAK
                            inhibitor approved without a platelet requirement.
                        </p>
                    </div>
                    <div className="bg-white p-3 rounded-lg border border-teal-200">
                        <h5 className="font-semibold text-teal-900 text-sm mb-1">Momelotinib (Ojjaara¬Æ)</h5>
                        <p className="text-xs text-teal-700">
                            JAK1/2 + ACVR1 inhibitor. Uniquely addresses <strong>anemia</strong> in MF by inhibiting
                            hepcidin (via ACVR1), improving iron availability. Approved for MF with anemia.
                        </p>
                    </div>
                </div>
            </div>

            <div className="bg-rose-50 p-5 rounded-xl border border-rose-100 mt-4">
                <h4 className="font-bold text-rose-900 mb-2">üè• Allogeneic Stem Cell Transplant</h4>
                <p className="text-sm text-rose-800">
                    The <strong>only curative treatment</strong> for myelofibrosis. Reserved for intermediate-2
                    and high-risk patients who are transplant candidates (typically age &lt;70, good organ function).
                    Transplant-related mortality is ~15-25%, but long-term disease-free survival is 40-60%.
                    Ruxolitinib is often used as a <strong>bridge to transplant</strong> to reduce spleen size and
                    improve symptoms pre-transplant.
                </p>
            </div>
        </section>

        {/* Section 6: MPN Complications & Transformation */}
        <section className="bg-white rounded-2xl shadow-sm border border-gray-200 p-8">
            <h2 className="text-2xl font-bold text-gray-900 mb-4 flex items-center gap-2">
                <span className="text-orange-600">‚ö†Ô∏è</span> Complications & Disease Transformation
            </h2>
            <p className="text-gray-700 text-lg leading-relaxed mb-4">
                MPNs are chronic diseases that carry risks of both <strong>vascular complications</strong> and
                <strong> transformation</strong> to more aggressive diseases over time.
            </p>

            <div className="grid grid-cols-1 md:grid-cols-2 gap-4 my-4">
                <div className="bg-red-50 p-5 rounded-xl border border-red-100">
                    <h4 className="font-bold text-red-800 mb-2">ü´Ä Thrombosis ‚Äî The Major Killer</h4>
                    <p className="text-sm text-red-700">
                        Thrombosis is the <strong>leading cause of morbidity and mortality</strong> in PV and ET:
                    </p>
                    <ul className="text-sm text-red-700 space-y-1 pl-4 mt-2">
                        <li>‚Ä¢ <strong>Arterial</strong>: stroke, MI, peripheral arterial occlusion</li>
                        <li>‚Ä¢ <strong>Venous</strong>: DVT/PE, splanchnic vein thrombosis (Budd-Chiari syndrome,
                            portal vein thrombosis ‚Äî nearly pathognomonic for MPNs in young patients)</li>
                        <li>‚Ä¢ <strong>Microvascular</strong>: erythromelalgia, digital ischemia, ocular migraine</li>
                        <li>‚Ä¢ JAK2 mutation activates platelets, increases neutrophil extracellular traps (NETs),
                            and promotes endothelial dysfunction</li>
                    </ul>
                </div>
                <div className="bg-orange-50 p-5 rounded-xl border border-orange-100">
                    <h4 className="font-bold text-orange-800 mb-2">üîÑ Disease Evolution Pathways</h4>
                    <div className="bg-white rounded-lg border border-orange-200 overflow-hidden mt-2">
                        <table className="w-full text-xs">
                            <thead className="bg-orange-100">
                                <tr>
                                    <th className="px-3 py-2 text-left font-semibold text-orange-900">From</th>
                                    <th className="px-3 py-2 text-left font-semibold text-orange-900">To</th>
                                    <th className="px-3 py-2 text-left font-semibold text-orange-900">Risk (15yr)</th>
                                </tr>
                            </thead>
                            <tbody className="divide-y divide-orange-100">
                                <tr><td className="px-3 py-2 text-orange-800">PV</td><td className="px-3 py-2 text-orange-700">Post-PV MF</td><td className="px-3 py-2 text-orange-600">~10-15%</td></tr>
                                <tr><td className="px-3 py-2 text-orange-800">PV</td><td className="px-3 py-2 text-orange-700">AML</td><td className="px-3 py-2 text-orange-600">~3-5%</td></tr>
                                <tr><td className="px-3 py-2 text-orange-800">ET</td><td className="px-3 py-2 text-orange-700">Post-ET MF</td><td className="px-3 py-2 text-orange-600">~5-10%</td></tr>
                                <tr><td className="px-3 py-2 text-orange-800">ET</td><td className="px-3 py-2 text-orange-700">AML</td><td className="px-3 py-2 text-orange-600">~1-3%</td></tr>
                                <tr><td className="px-3 py-2 text-orange-800">MF</td><td className="px-3 py-2 text-orange-700">AML (blast phase)</td><td className="px-3 py-2 text-orange-600">~10-20%</td></tr>
                            </tbody>
                        </table>
                    </div>
                    <p className="text-xs text-orange-600 mt-2 italic">
                        Blast-phase MPN (AML from prior MPN) has very poor outcomes with standard chemotherapy.
                    </p>
                </div>
            </div>

            <div className="bg-sky-50 p-5 rounded-xl border border-sky-100">
                <h4 className="font-bold text-sky-900 mb-2">üîÆ Emerging MPN Therapies</h4>
                <p className="text-sm text-sky-800">
                    Active areas of MPN drug development include: <strong>pelabresib</strong> (BET inhibitor ‚Äî
                    reduces bone marrow fibrosis when combined with ruxolitinib), <strong>imetelstat</strong>
                    (telomerase inhibitor showing disease-modifying potential in MF), <strong>navtemadlin</strong>
                    (MDM2 inhibitor targeting TP53 pathway), and combinations of JAK inhibitors with
                    <strong> BCL-2/BCL-xL inhibitors</strong> to target the MPN stem cell. The goal is moving beyond
                    symptom control toward <strong>true disease modification</strong> and clone elimination.
                </p>
            </div>
        </section>

        {/* Section 7: External Resources */}
        <section className="bg-white rounded-2xl shadow-sm border border-gray-200 p-8">
            <h2 className="text-2xl font-bold text-gray-900 mb-4 flex items-center gap-2">
                <span className="text-blue-600">üìö</span> Authoritative MPN Resources
            </h2>
            <p className="text-gray-700 leading-relaxed mb-6">
                These trusted organizations provide comprehensive, up-to-date information about MPNs:
            </p>
            <div className="grid grid-cols-1 md:grid-cols-2 gap-4">
                <a href="https://bloodcancerunited.org/blood-cancer/mpn"
                    target="_blank" rel="noopener noreferrer"
                    className="p-4 bg-blue-50 rounded-xl border border-blue-100 hover:border-blue-300 hover:shadow-md transition-all group">
                    <h4 className="font-bold text-blue-800 group-hover:text-blue-900 mb-1">Blood Cancer United ‚Äî MPN</h4>
                    <p className="text-sm text-blue-600">Comprehensive MPN overview including PV, ET, and MF.</p>
                    <span className="text-xs text-blue-500 font-semibold mt-2 inline-block">Visit ‚Üí</span>
                </a>
                <a href="https://www.mpnresearchfoundation.org"
                    target="_blank" rel="noopener noreferrer"
                    className="p-4 bg-rose-50 rounded-xl border border-rose-100 hover:border-rose-300 hover:shadow-md transition-all group">
                    <h4 className="font-bold text-rose-800 group-hover:text-rose-900 mb-1">MPN Research Foundation</h4>
                    <p className="text-sm text-rose-600">Funding MPN research and providing patient education resources.</p>
                    <span className="text-xs text-rose-500 font-semibold mt-2 inline-block">Visit ‚Üí</span>
                </a>
                <a href="https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq"
                    target="_blank" rel="noopener noreferrer"
                    className="p-4 bg-green-50 rounded-xl border border-green-100 hover:border-green-300 hover:shadow-md transition-all group">
                    <h4 className="font-bold text-green-800 group-hover:text-green-900 mb-1">NCI ‚Äî MPN Treatment (PDQ¬Æ)</h4>
                    <p className="text-sm text-green-600">Detailed treatment information reviewed by oncology experts.</p>
                    <span className="text-xs text-green-500 font-semibold mt-2 inline-block">Visit ‚Üí</span>
                </a>
                <a href="https://www.lls.org/myeloproliferative-neoplasms"
                    target="_blank" rel="noopener noreferrer"
                    className="p-4 bg-orange-50 rounded-xl border border-orange-100 hover:border-orange-300 hover:shadow-md transition-all group">
                    <h4 className="font-bold text-orange-800 group-hover:text-orange-900 mb-1">LLS ‚Äî Myeloproliferative Neoplasms</h4>
                    <p className="text-sm text-orange-600">Patient guides, community forums, and financial assistance programs.</p>
                    <span className="text-xs text-orange-500 font-semibold mt-2 inline-block">Visit ‚Üí</span>
                </a>
            </div>
        </section>
    </div>
);

export default MPNDeepDive;
